Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025

Spyre Therapeutics, Inc.

Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.
Raised $230M in November 2024 public offering; Q4 net cash used in operations $37.2M.
Interim Phase 1 data for SPY001 (α4β7) shows half-life >90 days supporting Q6M dosing; Phase 2 UC trial mid-2025.
SPY002 (TL1A) Phase 1 interim data expected Q2 2025; Phase 2 RA trial initiation mid-2025; top-line 2026.
SPY003 (IL-23) FIH trial starts Q1 2025 with interim data H2 2025; Phase 2 platform trial mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.